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Chronic intoxication causes abnormal thyroid function and
various neurological disorders.
doi:10.1016/j.ijid.2010.02.1513
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Epidemiology of Chronic Viral Hepatitis in Latin America
D. Diament
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil
Chronic viral hepatitis caused by Hepatitis B or C viruses
are major health problems in this beginning of the 21st
century. Estimated prevalence in the world population in
different regions range between less than 1% to more than
3% for HCV and between less than 2% to more than 8% for
HBV, affecting more than 400 million people in the world. In
Latin America, prevalence estimates are ﬂawed. For HCV it
varies from less than 1% to 2%, and for HBV from less than
1% to more than 8%. Numbers can be as high as 15% in the
Amazon region.
In Latin America, some surveys report HBV prevalence
as high as 21.4% in Dominican Republic and 7.9% in Brazil,
followed by 3.2% in Venezuela and 2.1% in Argentina. Low
prevalence was found in Mexico (1.4%) and Chile (0.6%). For
HCV, rough estimates project more than 10 million infected
people. Many surveys were conducted by blood banks, but
results are biased by sampling problems.
In Brazil, HCV prevalence studies estimates had found a
wide range, varying from 0.4% to 5.9%. A population based
study in 2007 found a HCV antibodies prevalence of 0.28%
to 2.61% and a HCV-RNA from 0.02% to 0.9% in different
regions of the country. From 1994 to 2005, the Ministry of
Health database has registered 52,440 HCV cases. Recently,
a national survey was conducted by the Ministry of Health,
but results are not published yet.
In São Paulo state, there were 30,299 HCV cases regis-
tered from 2002 to 2008 and 14,810 HBV cases in the same
period. In the city of São Paulo it is estimated a mean
prevalence of 1.42% (95% conﬁdence interval 0.7 — 2.12%).
Diagnosis can be done with blood tests, but availability is a
concern in poor countries.
Treatment is expensive and fairly effective, implying in
high morbidity, mortality and costs. Chronic hepatitis is a
great challenge for the health systems in Latin America.
doi:10.1016/j.ijid.2010.02.1514
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Update on Hepatits B Therapy
E. Savio
Universidad de la Repùblica, Montevideo, Uruguay
Tha main goal for the treatment of chronic hepatitis
B (CHB) is to prevent advanced hepatic disease: cirro-
sis,hepatic failure and hepatocellular carcinoma (HCC).
The ﬁrst aim of treatment is to achieve sustained suppre-
sion of HBV replication as well as the remission of liver
disease.The sustained supression of virological replication
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aries widely,depending on the population on treatment,
herapeutic agent s, treatment duration and less clearly
rom genotype. Since 1992,eigth therapeutic agents have
een approved worlwide (INF alfa, lamivudine, adefovir,
ntecavir, PegINF alfa-2a thymosin alfa1, ,telvibudine and
enofovir) but only some of them are used in different coun-
ries according to national regulation.. When and how to
reat an CHB depends on the HBV DNA levels, ALT and status
f HBeAg. For HBeAg(+) patients,the endpoint of treatment
s HBeAg seroconvertion. Therapy is considered in GHB with
BV DNA leves of 20.000 IU/ml or higer (HBeAg positive
atient) or 2.000 IU/ml (HBeAg negative), although lower
BV DNA levels migth be selected when evidences of pro-
resive disease are identiﬁed. ALT normalization and HBV
NA suppression are the measures of reponse to therapy.
ral nucleoside analogs (NA) is a signiﬁcant contribution for
reatment in the last years,but a major concern with this
gents is the selection of antiviral resistant mutations. This
ay be identiﬁed prior to virological breakthrough or at the
ame time. Peginterferon alfa-2a, entecavir and tenofovir
re currently included in the ﬁrst-line treatment choice on
he basis of their potency as well as the low rate of antiviral
rug resistance. The strategy of drugs combination in CHB
reatment for achieving a sustained virological response and
ome end points has beeen explored and the level of HBV
NA suppression. This combination theraphy is encouraging
n some clinical trials.
oi:10.1016/j.ijid.2010.02.1515
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. Sarmento e Castro
Hospital Joaquim Urbano, Porto, Portugal
Therapy of chronic HCV infection is based on the use
f the combination of pegylated interferon and ribavirin.
ustained virological response (SVR), a negative HCV RNA
4 weeks following discontinuation of therapy, is the most
mportant surrogate parameter to achieve. Actually, SVR is
btained in about 50% of patients with genotypes 1/4 and in
0% of the patients with genotypes 2/3.
Patients infected with genotypes 1 or 4 must be treated
or 48 weeks. But, if the patient achieves a rapid virological
esponse (RVR), deﬁned as a negative HCV RNA at week 4, we
an consider a shortening of treatment. In patients with a
low response to treatment (HCV RNA only negative between
eeks 12 and 24) the length of therapy must be extended
o 72 weeks. For patients infected with genotypes 2 or 3
reatment should be planned for 24 weeks.
New drugs are needed for non-responders and for those
ho are not good candidates to treatment.
Several new oral agents, more potent, less toxic and
llowing for shorter duration of treatment are being devel-
ped. These new drugs are designed to inhibit several viral
nzymes. Results of recent clinical trials using inhibitors of
S3/4A protease or inhibitors of NS5B polymerase in com-
ination with peginterferon/ribavirin are promising. These
tudies demonstrated that adding telaprevir or boceprevir
the protease inhibitors in the most advanced phases of eval-
ation) to peginterferon/ribavirin improved the rates of SVR
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n treatment-naïve and treatment-experienced patients.
rom these and other trials it was possible to conclude that
he use of these new agents in monotherapy, owing to its
elative low genetic barrier, was associated with a rapid
evelopment of resistance to the drugs and that the use
f ribavirin was always necessary. These new agents will be
vailable for general clinical use in the next years but they
ust be used as a complement of current therapy.
oi:10.1016/j.ijid.2010.02.1516
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anagement of HIV and Hepatitis C Co-infection
. Brito
University of Illinois, Chicago, IL, USA
The rate of coinfection of HIV with Hepatitis C is high
n countries where the mode of transmission is predomi-
antly intravenous drug abuse. The success of highly active
ntiretroviral therapy (HAART) in decreasing HIV related
orbidity and mortality has shifted the focus of care for
eople living with HIV. More attention is being paid to the
anagement and prevention of chronic ailments such as car-
iovascular, liver and renal disease. Thus, it is important
or the clinician treating HIV infected patients to recog-
ize the clinical presentations, spectrum of disease, efﬁcacy
f treatment and principles of management for coinfected
atients. Patients coinfected with the HIV and Hepatitis C
iruses have an increased risk of liver related morbidity and
more rapid progression to end-stage liver disease. The
reatment of these patients is complex owing to the signiﬁ-
ant side effects and limited efﬁcacy of Peg Interferon and
ibavirin. This lecture will review the epidemiology, nat-
ral history, diagnosis, management and newer treatment
odalities in HIV/HCV coinfection.
oi:10.1016/j.ijid.2010.02.1517
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nfectious diseases and infection control after natural dis-
sters
. Ambrosioni ∗, D. Lew, I. Uc¸kay
University Hospitals of Geneva, Geneva, Switzerland
Infections are frequent complications after natural
atastrophes. Previous reports suggest a high prevalence
f colonisation and infection with multi-resistant Gram-
egative pathogens in victims of natural disasters.
Literature regarding infections and infection control
easures after natural disasters was reviewed from 1986
hrough the end of 2009, with special emphasis on the 2004
sunami. Local microbiology of patients followed in our insti-
ution was also reviewed.Patients admitted after natural disasters often have
olymicrobial infections with atypical bacteria and fungi.
oreover, they are usually colonised or infected with
ulti-drug resistant organisms. These pathogens are
a
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cquired either nosocomially or environmentally. Sev-
ral studies have suggested that Gram-negative bacteria
re more prevalent than Gram-positive bacteria. A high
ncidence of colonisation and infection with extended
pectrum -lactamase-producing bacteria, multi-resistant
on-fermenting Gram-negative rods and difﬁcult to treat
ungal infections are found in these patients and may pose
hallenges in routine hospital care.
According to published date and our own experience,
e recommend pre-emptive contact isolation for victims
f natural disasters during hospitalisation until results of
icrobiological cultures become available. If respiratory
ymptoms are present, droplet isolation must be included.
hese measures should also be applied during the air
ransportation of these patients. Considering the differ-
nt multi-resistant colonisers, cohorting patients must be
voided whenever possible. In cases of life-threatening
nfections, empiric antibiotic therapy must cover multi-
esistant non-fermenting Gram-negative rods. Clinicians
ust be aware of unusual microbiological ﬁndings in these
atients.
oi:10.1016/j.ijid.2010.02.1518
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nfectious diseases and war conﬂicts in the Middle East
. Shibl
King Saud University, Ryadh, Saudi Arabia
Infectious diseases and war have been witnessed for as
ong as human life. Historically, infectious diseases have
een responsible for the majority of deaths during war;
owever, numerous medical and military advances have
eversed this trend, resulting in more deaths from bat-
le than infectious diseases in the 20th century. Wounds
ncurred in war are grossly contaminated with bacteria and
ost will become infected unless appropriate treatment is
nitiated quickly.Common infections include respiratory as
ell as gastrointestinal infections. Endemic diseases are also
eported during the war and they include Brucella, Q-fever,
alaria, Sandﬂy fever and Leishmaniasis. Non-battle injuries
uch as mental and combat stress are common; while battle
ssociated infections such as trauma- related complications
re extensively reported.
Multidrug resistances (MDR) Gram negative bacilli have
een reported in war wound infections, particularly Acine-
obacter spp, Enterobacter spp.and Pseudomonas spp. and
herefore empirical treatment for infected war wounds
hould be given to cover MDR. Other war related infec-
ions such as malaria, MDR tuberculosis, chronic Q fever and
rucellosis may become apparent after returning home and
herefore they should be considered due to their lengthy
eactivation periods. In addition to this, vaccines have
roven to be an important breakthrough to help prevent the
pread of several infectious diseases.
War wounds are predisposed to infection due to envi-
onmental conditions on the battleﬁeld, devitalized tissue,
nd foreign bodies in the wound as well as delays in
vacuating causalities. Knowledge of likely pathogens for
articular infections and sites, as well as optimal antibi-
tics to eradicate those pathogens will aid battleﬁeld
